{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:12:45Z","timestamp":1793157165757,"version":"4.5.0"},"reference-count":85,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>We highlight novel and emerging therapies in the treatment of childhood-onset movement disorders. We structured this review by therapeutic entity (small molecule drugs, RNA-targeted therapeutics, gene replacement therapy, and neuromodulation), recognizing that there are two main approaches to treatment: symptomatic (based on phenomenology) and molecular mechanism-based therapy or \u2018precision medicine\u2019 (which is disease-modifying).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>We highlight reports of new small molecule drugs for Tourette syndrome, Friedreich's ataxia and Rett syndrome. We also discuss developments in gene therapy for aromatic l-amino acid decarboxylase deficiency and hereditary spastic paraplegia, as well as current work exploring optimization of deep brain stimulation and lesioning with focused ultrasound.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Childhood-onset movement disorders have traditionally been treated symptomatically based on phenomenology, but focus has recently shifted toward targeted molecular mechanism-based therapeutics. The development of precision therapies is driven by increasing capabilities for genetic testing and a better delineation of the underlying disease mechanisms. We highlight novel and exciting approaches to the treatment of genetic childhood-onset movement disorders while also discussing general challenges in therapy development for rare diseases. We provide a framework for molecular mechanism-based treatment approaches, a summary of specific treatments for various movement disorders, and a clinical trial readiness framework.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001354","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T07:03:19Z","timestamp":1713942199000},"page":"331-341","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Emerging therapies for childhood-onset movement disorders"],"prefix":"10.1097","volume":"36","author":[{"given":"Lindsey","family":"Vogt","sequence":"first","affiliation":[{"name":"Division of Neurology, Department of Pediatrics, The Hospital for Sick Children, Toronto Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Quiroz","sequence":"additional","affiliation":[{"name":"Movement Disorders Program, Department of Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Ebrahimi-Fakhari","sequence":"additional","affiliation":[{"name":"Movement Disorders Program, Department of Neurology"},{"name":"F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","article-title":"Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders","volume":"92","author":"Pringsheim","year":"2019","journal-title":"Neurology"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"e2022059574","DOI":"10.1542\/peds.2022-059574","article-title":"Ecopipam for Tourette syndrome: a randomized trial","volume":"151","author":"Gilbert","year":"2023","journal-title":"Pediatrics"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"e1511","DOI":"10.1212\/WNL.0000000000200927","article-title":"The phenotypic continuum of ATP1A3-related disorders","volume":"99","author":"Vezyroglou","year":"2022","journal-title":"Neurology"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"A4","DOI":"10.1016\/j.ejpn.2021.05.004","article-title":"Revision of the diagnostic criteria of alternating hemiplegia of childhood","volume":"32","author":"Mikati","year":"2021","journal-title":"Eur J Paediatr Neurol"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/mds.29357","article-title":"Oxygen therapy: an acute treatment for paroxysmal dystonia in alternating hemiplegia of childhood?","volume":"38","author":"Welniarz","year":"2023","journal-title":"Mov Disord"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/mds.29561","article-title":"Effect of oxygen administration on paroxysmal motor events in alternating hemiplegia of childhood","volume":"38","author":"Papadopoulou","year":"2023","journal-title":"Mov Disord"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0883073818773028","article-title":"Medical cannabis for pediatric moderate to severe complex motor disorders","volume":"33","author":"Libzon","year":"2018","journal-title":"J Child Neurol"},{"issue":"(Pt 12)","key":"R8-20250730","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1093\/brain\/awv317","article-title":"The evolving spectrum of PRRT2-associated paroxysmal diseases","volume":"138","author":"Ebrahimi-Fakhari","year":"2015","journal-title":"Brain"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mdc3.13394","article-title":"Lisdexamfetamine therapy in paroxysmal nonkinesigenic dyskinesia associated with the KCNMA1-N999S variant","volume":"9","author":"Keros","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/mds.28138","article-title":"A gain-of-function mutation in KCNMA1 causes dystonia spells controlled with stimulant therapy","volume":"35","author":"Zhang","year":"2020","journal-title":"Mov Disord"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mdc3.12608","article-title":"Methylphenidate can improve chorea in NKX2.1 and ADCY5 mutation-positive patients-a report of two children","volume":"5","author":"Tubing","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5334\/tohm.372","article-title":"The movement disorder of brain-lung-thyroid syndrome can be responsive to methylphenidate","volume":"7","author":"Gauquelin","year":"2017","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/mdc3.13796","article-title":"Scoping review on ADCY5-related movement disorders","volume":"10","author":"Menon","year":"2023","journal-title":"Mov Disord Clin Pract"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ana.24119","article-title":"Gain-of-function ADCY5 mutations in familial dyskinesia with facial myokymia","volume":"75","author":"Chen","year":"2014","journal-title":"Ann Neurol"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/mds.29006","article-title":"Efficacy of caffeine in ADCY5-related dyskinesia: a retrospective study","volume":"37","author":"Meneret","year":"2022","journal-title":"Mov Disord"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"105409","DOI":"10.1016\/j.parkreldis.2023.105409","article-title":"Clinical, imaging and genetic profile of twenty-four patients with pantothenate kinase-associated neurodegeneration (PKAN)- a single centre study from India","volume":"111","author":"Sriram","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1474-4422(19)30142-5","article-title":"Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study","volume":"18","author":"Klopstock","year":"2019","journal-title":"Lancet Neurol"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5334\/tohm.661","article-title":"Towards precision therapies for inherited disorders of neurodegeneration with brain iron accumulation","volume":"11","author":"Spaull","year":"2021","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fncel.2018.00188","article-title":"Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich's ataxia models","volume":"12","author":"Abeti","year":"2018","journal-title":"Front Cell Neurosci"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann Neurol"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/acn3.51897","article-title":"Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data","volume":"11","author":"Lynch","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s12311-023-01568-8","article-title":"A milestone in the treatment of ataxias: approval of omaveloxolone for Friedreich ataxia","volume":"23","author":"Subramony","year":"2023","journal-title":"Cerebellum"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"1284035","DOI":"10.3389\/fphar.2023.1284035","article-title":"Trofinetide-a new chapter in rett syndrome's treatment","volume":"14","author":"Furqan","year":"2023","journal-title":"Front Pharmacol"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","volume":"29","author":"Neul","year":"2023","journal-title":"Nat Med"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41467-023-44264-1","article-title":"High-content screening identifies a small molecule that restores AP-4-dependent protein trafficking in neuronal models of AP-4-associated hereditary spastic paraplegia","volume":"15","author":"Saffari","year":"2024","journal-title":"Nat Commun"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"eabn9350","DOI":"10.1126\/sciadv.abn9350","article-title":"Restoration of the GTPase activity and cellular interactions of Galpha(o) mutants by Zn(2+) in GNAO1 encephalopathy models","volume":"8","author":"Larasati","year":"2022","journal-title":"Sci Adv"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/15476286.2022.2066334","article-title":"Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases","volume":"19","author":"Holm","year":"2022","journal-title":"RNA Biol"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/brain\/awz328","article-title":"Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders","volume":"143","author":"Silva","year":"2020","journal-title":"Brain"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin expression in patients with Huntington's Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMc2300400","article-title":"Tominersen in adults with manifest Huntington's disease","volume":"389","author":"McColgan","year":"2023","journal-title":"N Engl J Med"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","article-title":"A framework for individualized splice-switching oligonucleotide therapy","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"issue":"(Suppl 1)","key":"R33-20250730","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.pedneo.2022.09.004","article-title":"Adeno-associated virus vector-based gene therapies for pediatric diseases","volume":"64","author":"Muramatsu","year":"2023","journal-title":"Pediatr Neonatol"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders","volume":"22","author":"Ling","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/jnnp-2019-322327","article-title":"Great expectations: virus-mediated gene therapy in neurological disorders","volume":"91","author":"Kariyawasam","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"e0282593","DOI":"10.1371\/journal.pone.0282593","article-title":"Effects of theophylline on ADCY5 activation-From cellular studies to improved therapeutic options for ADCY5-related dyskinesia patients","volume":"18","author":"Tanzler","year":"2023","journal-title":"PLoS One"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1212\/WNL.43.1_Part_1.36","article-title":"Alternating hemiplegia of childhood: a study of 10 patients and results of flunarizine treatment","volume":"43","author":"Silver","year":"1993","journal-title":"Neurology"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-2008-1052478","article-title":"Flunarizine in alternating hemiplegia in childhood. An international study in 12 children","volume":"18","author":"Casaer","year":"1987","journal-title":"Neuropediatrics"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/mds.28788","article-title":"Nicotinamide riboside improves ataxia scores and immunoglobulin levels in ataxia telangiectasia","volume":"36","author":"Veenhuis","year":"2021","journal-title":"Mov Disord"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0022-3476(99)70424-5","article-title":"Treatment of ataxia in isolated vitamin E deficiency caused by alpha-tocopherol transfer protein deficiency","volume":"134","author":"Schuelke","year":"1999","journal-title":"J Pediatr"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10545-018-0162-7","article-title":"Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes","volume":"41","author":"Amador","year":"2018","journal-title":"J Inherit Metab Dis"},{"issue":"(2 (Pt 1))","key":"R44-20250730","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1212\/WNL.41.2_Part_1.174","article-title":"Dopa-responsive dystonia: long-term treatment response and prognosis","volume":"41","author":"Nygaard","year":"1991","journal-title":"Neurology"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"703970","DOI":"10.3389\/fneur.2021.703970","article-title":"Therapeutic Potential of sodium channel blockers as a targeted therapy approach in KCNA1-associated episodic ataxia and a comprehensive review of the literature","volume":"12","author":"Lauxmann","year":"2021","journal-title":"Front Neurol"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.nurt.2007.01.014","article-title":"Episodic ataxia type 2","volume":"4","author":"Strupp","year":"2007","journal-title":"Neurotherapeutics"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1212\/01.WNL.0000125691.74109.53","article-title":"Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine","volume":"62","author":"Strupp","year":"2004","journal-title":"Neurology"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/mds.25138","article-title":"Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder","volume":"27","author":"Stamelou","year":"2012","journal-title":"Mov Disord"},{"key":"R49-20250730","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1212\/WNL.0000000000002631","article-title":"A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia","volume":"86","author":"Hainque","year":"2016","journal-title":"Neurology"},{"key":"R50-20250730","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/0883073814531822","article-title":"Long-term clinical course of Glut1 deficiency syndrome","volume":"30","author":"Alter","year":"2015","journal-title":"J Child Neurol"},{"key":"R51-20250730","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/WNF.0000000000000149","article-title":"Effective treatment of paroxysmal nonkinesigenic dyskinesia with oxcarbazepine","volume":"39","author":"Kumar","year":"2016","journal-title":"Clin Neuropharmacol"},{"key":"R52-20250730","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jns.2012.08.015","article-title":"Familial paroxysmal nonkinesigenic dyskinesia: clinical and genetic analysis of a Taiwanese family","volume":"323","author":"Yeh","year":"2012","journal-title":"J Neurol Sci"},{"key":"R53-20250730","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10545-016-0011-5","article-title":"Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes","volume":"40","author":"Sofou","year":"2017","journal-title":"J Inherit Metab Dis"},{"key":"R54-20250730","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1750-1172-9-92","article-title":"Thiamine transporter-2 deficiency: outcome and treatment monitoring","volume":"9","author":"Ortigoza-Escobar","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"R55-20250730","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/hep.32805","article-title":"A multidisciplinary approach to the diagnosis and management of Wilson disease: executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases","volume":"77","author":"Schilsky","year":"2023","journal-title":"Hepatology"},{"key":"R56-20250730","doi-asserted-by":"crossref","first-page":"2210555","DOI":"10.1155\/2022\/2210555","article-title":"Clinical features in aromatic L-amino acid decarboxylase (AADC) deficiency: a systematic review","volume":"2022","author":"Rizzi","year":"2022","journal-title":"Behav Neurol"},{"key":"R57-20250730","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ajmg.c.31670","article-title":"A review of aromatic l-amino acid decarboxylase (AADC) deficiency in Taiwan","volume":"181","author":"Lee","year":"2019","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"R58-20250730","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1038\/s41467-021-24524-8","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons","volume":"12","author":"Pearson","year":"2021","journal-title":"Nat Commun"},{"key":"R59-20250730","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","article-title":"Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency","volume":"30","author":"Tai","year":"2022","journal-title":"Mol Ther"},{"key":"R60-20250730","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/mdc3.13685","article-title":"Intraputaminal gene delivery in two patients with aromatic L-amino acid decarboxylase deficiency","volume":"10","author":"Francois-Heude","year":"2023","journal-title":"Mov Disord Clin Pract"},{"key":"R61-20250730","first-page":"1427","article-title":"Eladocagene exuparvovec: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"R62-20250730","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1007\/s12325-023-02689-6","article-title":"Long-term outcomes of eladocagene exuparvovec compared with standard of care in aromatic L-amino acid decarboxylase (AADC) deficiency: a modelling study","volume":"40","author":"Simons","year":"2023","journal-title":"Adv Ther"},{"key":"R63-20250730","doi-asserted-by":"crossref","first-page":"e164575","DOI":"10.1172\/JCI164575","article-title":"Intrathecal AAV9\/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies","volume":"133","author":"Chen","year":"2023","journal-title":"J Clin Invest"},{"key":"R64-20250730","first-page":"280","article-title":"Sickle cell disease approvals include first CRISPR gene editing therapy","volume":"331","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"R65-20250730","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2741\/4586","article-title":"Deep brain stimulation: foundations and future trends","volume":"23","author":"Aum","year":"2018","journal-title":"Front Biosci (Landmark Ed)"},{"key":"R66-20250730","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/dmcn.14063","article-title":"Deep brain stimulation for pediatric dystonia: a meta-analysis with individual participant data","volume":"61","author":"Elkaim","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"R67-20250730","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/mds.22802","article-title":"Long-term follow-up of DYT1 dystonia patients treated by deep brain stimulation: an open-label study","volume":"25","author":"Cif","year":"2010","journal-title":"Mov Disord"},{"key":"R68-20250730","article-title":"Deep brain stimulation for GNAO1-associated dystonia: a systematic review and meta-analysis","author":"Decraene","year":"2023","journal-title":"Neuromodulation"},{"key":"R69-20250730","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mdc3.13374","article-title":"GPi-DBS for KMT2B-associated dystonia: systematic review and meta-analysis","volume":"9","author":"Rajan","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"R70-20250730","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.parkreldis.2022.09.012","article-title":"ACTB gene mutation in combined dystonia-deafness syndrome with parkinsonism: expanding the phenotype and highlighting the long-term GPi DBS outcome","volume":"104","author":"Straccia","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"R71-20250730","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1007\/s00415-020-09871-8","article-title":"Deep brain stimulation reduces (nocturnal) dyskinetic exacerbations in patients with ADCY5 mutation: a case series","volume":"267","author":"de Almeida Marcelino","year":"2020","journal-title":"J Neurol"},{"key":"R72-20250730","article-title":"Broadening the clinical spectrum: molecular mechanisms and new phenotypes of ANO3-dystonia","author":"Ousingsawat","year":"2023","journal-title":"Brain"},{"key":"R73-20250730","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/mdc3.13371","article-title":"Heterozygous EIF2AK2 variant causes adolescence-onset generalized dystonia partially responsive to DBS","volume":"9","author":"Magrinelli","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"R74-20250730","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejpn.2008.01.006","article-title":"Deep brain stimulation as a mode of treatment of early onset pantothenate kinase-associated neurodegeneration","volume":"13","author":"Mikati","year":"2009","journal-title":"Eur J Paediatr Neurol"},{"key":"R75-20250730","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mds.27474","article-title":"Long-term GPi-DBS improves motor features in myoclonus-dystonia and enhances social adjustment","volume":"34","author":"Kosutzka","year":"2019","journal-title":"Mov Disord"},{"key":"R76-20250730","first-page":"105949","article-title":"A scoping review on the diagnosis and treatment of X-linked dystonia-parkinsonism","author":"Alonto","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"key":"R77-20250730","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1007\/s00415-015-7908-z","article-title":"Long-term effect on dystonia after pallidal deep brain stimulation (DBS) in three members of a family with a THAP1 mutation","volume":"262","author":"Krause","year":"2015","journal-title":"J Neurol"},{"key":"R78-20250730","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/mds.29428","article-title":"Deep brain stimulation for medically refractory status dystonicus in UBA5-related disorder","volume":"38","author":"Zaman","year":"2023","journal-title":"Mov Disord"},{"key":"R79-20250730","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ana.26799","article-title":"Deep brain stimulation for refractory status dystonicus in children: multicenter case series and systematic review","volume":"95","author":"Vogt","year":"2024","journal-title":"Ann Neurol"},{"key":"R80-20250730","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/archdischild-2020-320907","article-title":"Neurosurgical management of elevated tone in childhood: interventions, indications and uncertainties","volume":"108","author":"Lumsden","year":"2023","journal-title":"Arch Dis Child"},{"key":"R81-20250730","doi-asserted-by":"crossref","first-page":"105438","DOI":"10.1016\/j.parkreldis.2023.105438","article-title":"The changing face of reported status dystonicus - a systematic review","volume":"112","author":"Lumsden","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"key":"R82-20250730","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamaneurol.2017.4317","article-title":"Efficacy and safety of deep brain stimulation in Tourette syndrome: the International Tourette Syndrome Deep Brain Stimulation Public Database and Registry","volume":"75","author":"Martinez-Ramirez","year":"2018","journal-title":"JAMA Neurol"},{"key":"R83-20250730","doi-asserted-by":"crossref","first-page":"e12874","DOI":"10.1016\/j.heliyon.2023.e12874","article-title":"Emerging therapies and recent advances for Tourette syndrome","volume":"9","author":"Chou","year":"2023","journal-title":"Heliyon"},{"key":"R84-20250730","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/WNL.0000000000011704","article-title":"The 5 pillars in Tourette syndrome deep brain stimulation patient selection: present and future","volume":"96","author":"Martino","year":"2021","journal-title":"Neurology"},{"key":"R85-20250730","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3171\/2021.11.JNS21928","article-title":"Deep brain stimulation for extreme behaviors associated with autism spectrum disorder converges on a common pathway: a systematic review and connectomic analysis","volume":"137","author":"Yan","year":"2022","journal-title":"J Neurosurg"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:03:43Z","timestamp":1753898623000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001354","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]}}}